Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2011

View Archived Issues

Sanofi-aventis profiles progress of fourth quarter 2010

Additional phase II data reported on paclitaxel nanoparticles in urothelial cancer

Aestus begins phase II trial of ATx08-001 for neuropathic pain after shingles outbreak

Lux Biosciences begins enrollment in phase III voclosporin trial in uveitis

Global Health Ventures begins clinical development of X-Excite in E.U.

Lee's Pharma receives rights to Gaslon N in China

NCI develops anticancer monoclonal antibodies targeting mesothelin

Phase II pazopanib trial in urothelial cancer closed due to lack of activity

Rare Disease Day / Recently launched orphan drugs

Everolimus is active in patients with transitional cell carcinoma of the urothelium

New NICE guidance recommends not using Avastin for metastatic breast cancer

Stemline Therapeutics licenses phase I/II brain cancer vaccine

Enrollment complete in first of two pivotal phase III efficacy trials of LibiGel

CEQ-508 does not have adverse effects in nonhuman primates

AMG-386/sorafenib combination shows promise in metastatic renal cell carcinoma

MolMed extends pivotal phase III trial of NGR-hTNF

Phase II TXA-127 trial begins in autologous peripheral blood stem cell transplantation

PolyMedix completes phase I safety study of PMX-30063

Sanofi-aventis acquires BMP Sunstone

FDA grants Genentech hearing on Avastin for metastatic breast cancer

Belgian researchers disclose new inhibitors of HIV replication

Green Cross discloses (+)-3-hydroxymorphinans for neurodegenerative diseases

Takeda presents novel PARP inhibitors

New protein kinase inhibitors disclosed

Theravance presents new inhibitors of norepinephrine and/or 5-HT reuptake

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...